The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Toll-like receptors (TLRs) are vital components of the immune system, acting as sentinels that detect and respond to ...

The adenine base editor corrected the most common mutation associated with Stargardt disease in the ABCA4 gene with no off-target effects.

Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular oedema ...

Shares of Outlook Therapeutics jumped after the company said it continues to progress the development of its treatment for wet age-related macular degeneration, which causes blurred or reduced central ...

Lenvatinib is under clinical development by AiViva BioPharma and currently in Phase II for Diabetic Macular Edema.

Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in ...

Shares of Outlook Therapeutics jumped after the company said it continues to progress the development of its treatment for wet age-related macular degeneration, which causes blurred or reduced ...

Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm. Under the agreement, ...

Jedd Comiskey, Senior Vice President, Head of Europe, highlights the recent NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the ...

Pravin U. Dugel, MD, Ocular's Executive Chairman, President and CEO, will provide an update regarding the enrollment status ...